Top News
SK Biopharmaceuticals Secures 795 Million USD License for Groundbreaking Epilepsy Drug...
SK Biopharmaceuticals acquires epilepsy drug candidate from Biohaven for 795 million USD, enhancing its global biotech portfolio.
- Our Sponsors Ad -